ARKUSDT
Ark / Tether USD
crypto Composite

Don’t look at her, look at the company data.
Anyway she’s only one fund that bought, have you seen Blue Owl has got a potential 1 million+ position? And there are more like Daytona, Apella, Mariner, Bank Of America etc.
These are only symptoms, shared the ARK story to get the “insider like” point across, but the reasons to buy are plenty and have nothing to do with any institution.

Yes, she had an abysmal run (for years), but has been on fire the last 18 months. Anyway DRTS getting added to one of her ETFs is a signal that it’s getting noticed. The reason to buy IS NOT Cathie Wood, the reason to buy is DRTS is the best risk/reward opportunity on the market imo, that’s why ARK bought and that’s why you should look into it.

So many scammy pumps for this based on like, 2 phase 1 patients. Yall about to get pantsed. No one comes on here writing stuff like this because they’re your friends.
Cathie Wood and ARK are a absolute disaster signal, like super rug pull about to happen.

Goldman Sachs’ reported Bitcoin holdings have fallen by 45% since its last regulatory filing, a decline driven almost entirely by Bitcoin’s price drop.
Based on fourth-quarter 2025 Form 13F disclosures, Goldman Sachs holds indirect exposure to approximately 13,741 Bitcoin through spot Bitcoin exchange-traded funds (ETFs).
The bulk of Goldman’s exposure sits in BlackRock’s iShares Bitcoin Trust (IBIT), where the bank holds more than 19 million shares, representing an estimated 11,400 BTC.
Additional positions include Fidelity’s Wise Origin Bitcoin Fund (FBTC), Grayscale’s Bitcoin Trust (GBTC), Bitwise’s BITB, and smaller allocations to ARK 21Shares, Invesco Galaxy and WisdomTree Bitcoin ETFs.
https://finance.yahoo.com/news/goldman-sachs-bitcoin-holdings-reveal-012602711.html

Since some of the gating is due to federal regulation, you can't directly bypass it. There may be ways for the business to be an Accredited Investor and let users own the right to your company's investments. It would require legal to be involved to see how it could be set up. ARK Invest has a new ETF like this.

Alpha Tau Medical (DRTS) has one of the best yet somehow unknown stories on the market.
A revolutionary cancer treatment that could treat all solid tumors even the most high unmet needs like Pancreas and GBM, with decades of work all coming together, as they have already started submitting Phase 3 data for FDA approval and are expecting PMDA approval in Japan as well.
But years of progress have gone by with virtually no PR, since the company is fully financed and didn’t need the attention.
That led to a community with sharp senses and great hunger for any kind of information, since official news and announcements were few and far apart.
And while all the info is public of course, following closely became an edge that is *insider-like*, and I’ll give you some examples.
Just this Monday, the community were the ones who broke the news about the second successfully treated GBM patient, by following the doctor leading the U.S. FDA trial.
The last update we got from the company was that the first GBM patient was successfully treated, and walked out of the hospital on his own strength the following day. But thanks to the community we now know a second patient has been treated and they are “both doing great”.
Then on Tuesday, the community uncovered that Blue Owl Capital has filed a one million+ position in the company.
That follows the community figuring out Cathie Wood and ARK were planning to take a two million+ position in the stock over a week prior to it happening(!), which came to fruition after many have front run it.
And maybe the most significant find, was a Japanese reporter that attended the PMDA approval committee, making it known that the market authorization is all but a formality and a matter of time, which will be turning the clinical-stage pre-revenue company into the potential commercial oncology platform it can become.
Even though DRTS already has 55+ clinical sites worldwide, FDA Breakthrough Device Designation, real life-saving in-human results, it somehow is stilll under the radar, creating one of the best risk/reward opportunities on the market.
NFA and DYOR, but the word is starting to spread between retail and institutions.

Alpha Tau Medical (DRTS) has one of the best yet somehow unknown stories on the market.
A revolutionary cancer treatment that could **treat all solid tumors even the most high unmet needs like Pancreas and GBM**, with decades of work all coming together, as they have already started submitting Phase 3 data for **FDA approval** and are expecting **PMDA approval** in Japan as well.
But years of progress have gone by with virtually no PR, since the company is **fully financed** and didn’t need the attention.
That led to a community with sharp senses and great hunger for any kind of information, since official news and announcements were few and far apart.
And while all the info is public of course, **following closely became an edge** that is *insider-like*, and I’ll give you some examples.
Just this Monday, the community were the ones who broke the news about the **second successfully treated GBM patient**, by following the doctor leading the U.S. FDA trial.
The last update we got from the company was that the first GBM patient was successfully treated, and walked out of the hospital on his own strength the following day. But thanks to the community we now know a second patient has been treated and they are **“both doing great”**.
Then on Tuesday, the community uncovered that **Blue Owl Capital** has filed a **one million+** position in the company.
That follows the community figuring out **Cathie Wood and ARK** were planning to take a **two million+** position in the stock over **a week prior to it happening(!)**, which came to fruition after many have front run it.
And maybe the most significant find, was a Japanese reporter that attended the **PMDA approval committee**, making it known that the market authorization is all but a formality and a matter of time, which will be turning the clinical-stage pre-revenue company into the potential **commercial oncology platform** it can become.
Even though DRTS already has **55+ clinical sites worldwide**, **FDA Breakthrough Device Designation**, **real life-saving in-human results**, it somehow is stilll under the radar, creating one of the best risk/reward opportunities on the market.
NFA and DYOR, but the word is starting to spread between retail and institutions.

waiting to see if ZRO dips after announcement. ARK backing is interesting but tokens usually dump

tldr; LayerZero Labs has announced the launch of its new layer-1 blockchain, 'Zero,' following strategic funding from ARK Invest and Citadel Securities. Zero is designed to support large-scale, institutional-grade trading, settlement, and tokenization, with a focus on scalability and low transaction costs. The blockchain aims to handle up to 2 million transactions per second using advanced technologies. ARK Invest and Citadel Securities join existing investors like a16z crypto and Sequoia Capital in backing LayerZero's initiatives.
*This summary is auto generated by a bot and not meant to replace reading the original article. As always, DYOR.

LayerZero announces Zero blockchain after strategic funding from ARK & Citadel

If you’re looking for a higher risk performance booster to a portfolio, may I recommend either [Avantis Emerging Markets Equity (Acc)](https://www.trading212.com/trading-instruments/invest/AVEG.GB) or [Avantis Global Small Cap Value (Acc)](https://www.trading212.com/trading-instruments/invest/AVSG.GB)? They’re both cheaper than your two ETFs, are quite volatile, but have fantastic long run performance.
Alternatively, if it must be of the two you wish to select, ARK is much more traditional big tech (and is much more expensive), whereas GLOBAL X’s holdings include smaller more niche firms (and is cheaper). I suppose then it’s a case of who do you think will win the AI race? Traditional firms are a medium-sized competitor. If the former, pick ARK. If the latter, pick GLOBAL X.

Morning gang,
looking to finalise my pie, delete the app and check back in 10 years. But I'm stuck on a decision
I want to add in a robotics and or AI ETF which will only equate to maybe 7% of my pie, may even do it at 5% but I'm unsure on what to trade!
I'm UK based so I only pick the trades in P or £, the 2 ETFs I'm stuck between are ARK ARTIFICIAL INTELLIGENCE AND ROBOTICS (ARCI) & GLOBAL X ARTIFICIAL INTELLIGENCE (AIGH)
Any tech savvy people that dig these and for what reason? whilst there was/is so much AI hype there are many upcoming UK AI IPO's due in the next 2 years but I want to stray away from individual stocks, as an example I only hold Equinox gold and CSG. Equinox I bought a while back in the huge dip and plan on holding forever, CSG I got near IPO price and beat the initial surge and again plan on holding, rest of my portfolio is ETF based.
No random users and Reddit is not financial advice but often the comments come back with great feedback that beats a grueling history search